Scope and Claims Analysis of US Patent 10,814,002 (Asenapine Transdermal Patch) and U.S. Patent Landscape for Entry Risk
US Patent 10,814,002 protects a transdermal patch delivering asenapine via a pressure-sensitive adhesive (PSA) layer engineered around a specific adhesive composition and specific in-vivo pharmacokinetic (PK) performance targets. The claim set is drafted to secure both composition-of-matter style coverage (sodium diacetate generated from sodium acetate “in the presence of asenapine”) and functional exposure/receptor occupancy outcomes, creating multiple infringement hooks for later patch variants, formulation improvements, and “design-around” attempts that still hit the defined PK and exposure metrics.
What does US Patent 10,814,002 claim, and what is the protected technology core?
Core protection (independent claim 1): A patch comprising
- Support layer and
- Adhesive agent layer containing:
- Sodium diacetate (explicitly generated from sodium acetate in the presence of asenapine and/or its pharmaceutically acceptable salt),
- A pressure-sensitive adhesive base agent, and
- Asenapine (or pharmaceutically acceptable salt).
Critical quantitative boundaries in claim 1
- Patch application surface area: 20 to 40 cm²
- Asenapine free content in adhesive layer: 6.4 to 12.8 mg (as free asenapine)
- PK after 24-hour skin contact:
- Cmax of free asenapine: 0.5 to 6.0 ng/mL
- Tmax of free asenapine: 8 to 28 hr
- Functional PK metabolite control (via dependent claims): metabolite AUC and Cmax are constrained relative to free asenapine.
Claim 1 is a “composition + device + performance” claim
The sodium diacetate requirement is not a generic excipient recitation. The claim ties the sodium diacetate to a manufacturing/chemical generation condition: “generated from sodium acetate in the presence of asenapine and/or salt.” That language is often where enforcement leverage sits, because later patch formulations may avoid adding sodium diacetate directly but still create it during processing. Conversely, design-arounds that use sodium diacetate but alter other defined ranges may avoid infringement if they fall outside the patch size, dose, or PK targets.
How broad are the claims across patch size, dose, and PK thresholds?
Claim breadth is segmented into multiple “gates.” A product must satisfy all gates for claim 1. Dependent claims then add additional gates.
Patch surface area gate
- Claim 1: 20 to 40 cm²
- Claim 8: 20 cm²
- Claim 9: 40 cm²
This structure means enforcement can target both end-point commercial formats (20 and 40 cm²) and the mid-range.
Dose gate (free asenapine in adhesive)
- Claim 1: 6.4 to 12.8 mg
- Claim 10: 6.4 mg
- Claim 17: 12.8 mg
Because claim 10 and 17 anchor single-dose endpoints, the patent is positioned to cover products tuned to those exact strengths.
PK Cmax gate after 24 hours
- Claim 1: Cmax (free asenapine) 0.5 to 6.0 ng/mL
This range can be used in litigation where accused patches are tested with defined protocols to show whether exposure sits within the claim window.
PK Tmax gate after 24 hours
- Claim 1: Tmax (free asenapine) 8 to 28 hr
Many transdermal designs influence rate of absorption; the claim ties not just overall exposure but absorption timing.
Metabolite formation control
Claims 4 and 5 limit metabolite relative exposure:
- Claim 4: metabolite Cmax ≤ 20% of free asenapine Cmax
- Claim 5: metabolite AUC0-inf ≤ 22% of free asenapine AUC0-inf
This is a second functional axis. Even if a competitor achieves similar parent PK, failing these metabolite ratio limits can avoid dependent-claim infringement.
Steady-state/functional pharmacodynamics gate (D2 occupancy)
- Claim 6: Dopamine D2 receptor occupancy 14% to 70% after once-daily use for 7 days
This is a PD endpoint that can be difficult to replicate, and it can become a high-leverage evidentiary target if a competitor’s clinical program produced the required D2 occupancy range.
What is the scope impact of sodium diacetate “generated from sodium acetate” in the presence of asenapine?
Claim 1 requires sodium diacetate in the adhesive layer, but it also requires a specific origin:
“sodium diacetate is generated from sodium acetate in the presence of the asenapine and/or pharmaceutically acceptable salt thereof.”
From a scope standpoint, this creates a conditional formulation requirement that can be read in two ways in practice:
- If the accused patch manufacturing creates sodium diacetate in-process, even if the label lists components differently, the “generated from” language supports causation-based infringement arguments.
- If a competitor tries to avoid sodium diacetate, it must avoid both:
- having sodium diacetate in the adhesive layer, and
- generating it from sodium acetate during formulation.
This kind of phrasing frequently targets a specific chemistry route and anchors infringement to analytical composition plus process causation.
What additional coverage do the dependent claims add beyond claim 1?
Metabolite limiting claims
- Claim 4 (metabolite Cmax ≤ 20% of free asenapine Cmax)
- Claim 5 (metabolite AUC0-inf ≤ 22% of free asenapine AUC0-inf)
Absorption enhancer option
- Claim 7: adhesive agent layer further comprises an absorption enhancer
This is not a narrowing limitation because it is optional (“further comprises”). It supports that the invention is compatible with known permeation modifiers while keeping the core PK/chemistry gates intact.
Fixed end-point embodiments
- Claim 8 and 9: 20 cm² and 40 cm²
- Claim 10 and 17: 6.4 mg and 12.8 mg
Specific salt embodiment (asenapine maleate)
- Claim 11 narrows asenapine salt to asenapine maleate
Then Claims 12-16 mirror Claims 2-6 for the maleate scenario:
- Claim 12: AUC0-inf of free asenapine ≥ 36 ng·hr/mL
- Claim 13: t1/2 of free asenapine 17 to 55 hr
- Claim 14: metabolite Cmax ≤ 20% of free asenapine Cmax
- Claim 15: metabolite AUC0-inf ≤ 22%
- Claim 16: D2 occupancy 14% to 70% after once daily for 7 days
Method-of-treatment claims
- Claim 18: method treating schizophrenia by administering the patch of claim 1
- Claim 19: method treating schizophrenia by administering the patch of claim 7
- Claim 20: method treating schizophrenia by administering the patch of claim 11
These are standard utility hooks. In practice, method claims can matter when:
- a device component is identical or close, but
- product labeling/indication and evidence of use are in dispute.
How do the claim-defined PK and PD metrics affect infringement proof?
US Patent enforcement against formulation/performance claims typically turns on test protocol alignment. The claim’s metric specificity helps the patentee build a direct mapping:
- Exposure magnitude: Cmax and AUC0-inf windows
- Exposure timing: Tmax window
- Duration profile: t1/2 window (dependent maleate claims)
- Metabolite suppression: metabolite ratios at Cmax and AUC0-inf
- Clinical pharmacology: D2 receptor occupancy range after multiple doses
If an accused product’s human PK/PD data is publicly available or discoverable from clinical/regulatory filings, it can be used to show presence or absence of each gate.
What is the likely claim-to-product matching strategy for competitors (design-around map)?
Competitors seeking to reduce infringement exposure typically attack one or more independent gates. The patent’s structure suggests the main levers are:
Lever A: PK timing and magnitude
- Move Cmax outside 0.5 to 6.0 ng/mL
- Move Tmax outside 8 to 28 hr
This can be targeted via changes in adhesive composition, patch thickness, drug loading distribution, or permeability.
Lever B: Drug amount / patch size
- Avoid 6.4 to 12.8 mg free asenapine in adhesive layer
- Avoid 20 to 40 cm² patch area
But note: claim coverage still exists at endpoints 6.4 mg, 12.8 mg, 20 cm², and 40 cm² through dependents, so “near miss” formulations should be measured carefully.
Lever C: Salt selection and maleate-specific dependent claims
Using salts other than asenapine maleate can avoid Claims 11-16, but claim 1 still covers “asenapine and/or pharmaceutically acceptable salt thereof” generally. So salt switching alone does not eliminate claim 1 risk.
Lever D: Sodium acetate chemistry to avoid sodium diacetate generation
If a competitor uses a PSA with acidic salts but designs to prevent sodium diacetate formation, it may target the key composition origin requirement. However, proving “no generated sodium diacetate” is difficult unless manufacturing and analytical chemistry are tightly controlled.
Lever E: Metabolite ratio and D2 occupancy
Even if parent exposure looks similar, failing:
- metabolite Cmax ≤ 20% and metabolite AUC ≤ 22% (dependent claims)
- D2 occupancy 14% to 70% after 7 days (dependent claims)
can help avoid dependent claims. But claim 1 does not include metabolite and D2 thresholds, so it remains a baseline risk.
How strong is the patent estate risk for asenapine transdermal patches in the U.S.?
What we can conclude from the claim set alone
Without the Orange Book listing or related family member documentation, strength analysis can still be anchored to the claim architecture:
- The patent is not limited to a generic “asenapine patch.” It is limited to a specific adhesive chemistry route and measurable PK/PD performance ranges.
- Those performance ranges generally correlate to human trial protocols. If a competitor has similar clinical endpoints, the patent becomes easier to assert and harder to design around.
- The presence of multiple dependent constraints (metabolite ratios and D2 occupancy) increases the probability that at least one dependent claim maps to an accused product profile, depending on which salt and loading are used.
How enforceability typically depends on evidence availability
- For products already in the market, the most practical enforcement evidence is often obtained from regulatory dossiers and bridging PK/PD studies.
- If competitors conducted studies matching these endpoints (Cmax, Tmax, AUC0-inf, t1/2, metabolite ratios, D2 occupancy), the evidentiary path is shorter.
What patent landscape items commonly interact with US 10,814,002 for asenapine patches?
A full landscape requires bibliographic retrieval across:
- the application family for 10,814,002,
- related continuation/divisional patents,
- method-of-treatment and formulation subfamilies,
- and likely later improvements around PSA matrices, adhesives, and permeation enhancers.
That retrieval is not present in the prompt, so a complete cross-patent map cannot be produced here.
What can be stated precisely from the claim text you provided is that 10,814,002 sits at the intersection of:
- transdermal device formulation
- in-vivo exposure control
- pharmacology-linked utility
This combination often results in clusters of other patents covering:
- specific PSA matrices and tackifiers,
- patch reservoir/adhesion architectures,
- drug loading and formulation stability,
- salt forms (including maleate),
- and PK/PD bridging claims.
When does US Patent 10,814,002 likely expire and how do exclusivity timelines usually affect entry?
This requires the patent’s:
- filing date (non-provisional priority),
- granted status and any PTA,
- and whether the patent is subject to terminal disclaimer.
Those data are not included in the prompt. Without them, an accurate U.S. patent expiration and exclusivity timeline cannot be stated.
Key Takeaways
- US Patent 10,814,002 protects an asenapine transdermal patch where a PSA adhesive layer includes sodium diacetate formed from sodium acetate in the presence of asenapine/salt, plus defined patch area (20–40 cm²) and dose (6.4–12.8 mg free asenapine).
- The independent claim 1 includes human PK performance gates after 24 hours: Cmax 0.5–6.0 ng/mL and Tmax 8–28 hr, which can be used directly in infringement testing.
- Dependent claims add higher specificity:
- Maleate-specific embodiment and associated AUC0-inf ≥ 36 ng·hr/mL, t1/2 17–55 hr
- Metabolite suppression (metabolite Cmax ≤ 20% and AUC ≤ 22% of parent)
- D2 receptor occupancy 14–70% after once-daily use for 7 days
- The sodium diacetate “generated from sodium acetate” language targets not only ingredient selection but process/formulation chemistry, raising the barrier for “simple excipient swaps.”
FAQs
1) Can a competitor avoid infringement by changing the asenapine salt form?
Switching away from asenapine maleate can avoid maleate-specific dependents (Claims 11–16), but claim 1 still covers “asenapine and/or pharmaceutically acceptable salt thereof.”
2) What PK endpoints matter most for claim 1 infringement risk?
For claim 1, the key human PK gates are Cmax (free asenapine) 0.5–6.0 ng/mL and Tmax 8–28 hr after 24 hours skin contact.
3) Does the patent require controlling asenapine metabolites?
Not for claim 1. Metabolite ratio constraints appear in dependent claims 4 and 5 (and in maleate dependents 14 and 15).
4) Is D2 receptor occupancy required for infringement?
Not for claim 1. D2 receptor occupancy is required in dependent claim 6 (and maleate dependent 16).
5) How can patch size and drug loading be used as design-around levers?
Altering patch area outside 20–40 cm² and/or moving free asenapine content outside 6.4–12.8 mg reduces claim 1 risk. Endpoints 20 cm² and 40 cm², and 6.4 mg and 12.8 mg, are explicitly captured in dependents.
References
- US Patent 10,814,002 (provided claims text by user).
